403485-90-5Relevant articles and documents
Palladium-Catalyzed Dehydrative Cross-Coupling of Allylic Alcohols and N-Heterocycles Promoted by a Bicyclic Bridgehead Phosphoramidite Ligand and an Acid Additive
Kang, Kyungjun,Kim, Jaewook,Lee, Ansoo,Kim, Woo Youn,Kim, Hyunwoo
supporting information, p. 616 - 619 (2016/02/18)
A mild and efficient dehydrative cross-coupling reaction between allylic alcohols and N-heterocycles using palladium catalysis is reported. A bicyclic bridgehead phosphoramidite (briphos) ligand together with Pd(dba)2 is a highly efficient catalyst, and an acid additive involved in the rate-determining step promotes the catalytic cycle. The coupling reaction of allylic alcohols with N-heterocycles including imidazoles, benzimidazoles, and triazole proceeds under mild reaction conditions with high yields using Pd/briphos and pentafluorophenol.
Sulfonated dye salts having improved stability
-
Page/Page column, (2014/04/17)
A sulfonated dye salt is disclosed. The sulfonated dye salt has a phosphazene cation of formula (C): wherein: R15, R16 and R17 are each independently selected from the group consisting of: C6-12 aryl, C5-12 heteroaryl; N(R20)(R21) and —N═P[N(R22)2]3;R18 and R19 are each independently selected from the group consisting of: H and C1-8 alkyl; or R18 and R19 are together: ═P(Ph)3;R20 and R21 are each independently selected from the group consisting of: H and C1-8 alkyl; or R20 and R21 are together joined to form a nitrogen-containing C5-10 heterocycloalkyl group; andR22 is C1-6 alkyl.
Novel farnesyl protein transferase inhibitors as antitumor agents
-
Page 181-182, (2010/02/07)
Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
Novel farnesyl protein transferase inhibitors as antitumor agents
-
Page 149, (2010/02/03)
Disclosed are novel tricyclic compounds represented by the formula (1.0): or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
